Dr. Reddy’s Laboratories announces the launch of sevelamer carbonate tablets in the U.S. market.
Dr. Reddy’s Laboratories Ltd. announced that it has launched Sevelamer Carbonate Tablets, 800 mg, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) tablets, approved by the U.S. Food and Drug Administration (USFDA).
“We are very pleased to bring Sevelamer Carbonate Tablets to market at this time,” says Alok Sonig, Executive Vice President and Head of the North America Generics business at Dr. Reddy’s. “This launch represents Dr. Reddy’s expertise and commitment to provide affordable alternatives for complex, limited-competition products to market.” This is the Company’s eighth overall and fourth limited-competition launch this fiscal year.
The Renvela brand and generic had U.S. sales of approximately $1.88 billion MAT for the most recent twelve months ending in July 2017 according to IMS Health*.
Dr. Reddy’s Sevelamer Carbonate Tablets, 800 mg are available in the bottle count size of 270 tablets.
________________________________________________________
Renvela® is a trademark of Genzyme Corporation
*IMS National Sales Perspective: Retail and Non-Retail MAT July 2017
(Source: Business Wire)
Follow Pharmaceutical Processing on Twitter, Facebook, and LinkedIn and subscribe to our YouTube channel for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
